|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Residual strength prediction of damaged composite fuselage panel with R-curve method 显示文摘 | Wang John T Poe Clarence C Jr Ambur Damodar R Sleight David W | 2006 | Composites Science and Technology2006，66，13： | 1 |
| 2 | Basic research at Exxon显示文摘 | CLARENCE M EIDT JR ROGER W COHEN | 1997 | Chemtech1997，，4： | 1 |
| 3 | The safety and effectiveness of endoscopic and non-endoscopic approaches to the management of early esophageal cancer:A systematic review显示文摘 | Paul M Tania S Clarence W | 2011 | Cancer Treatment Reviews2011，37，1： | 1 |
| 4 | Tracking control of an electrohydraulic manipulator in the presence of friction显示文摘 | Tafazoli S Clarence W Lawrence P D | 1998 | EEE Transactions on Control Systems Technology1998，6，3： | 1 |
| 5 | Reconstruction equations and the Karhunen-Loeve expansion for systems with symmetry 显示文摘 | Clarence R W Jerrold M E | 2000 | Physica D2000，142，： | 1 |
| 6 | A hybrid visual servocontroller for robust grasping by wheeled mobile robots 显示文摘 | Wang Y Lang H X Clarence W S | 2010 | IEEE/ASME Transactions on Mechatronics2010，15，5： | 1 |
| 7 | Toxicity of ear- baryl and malathion to two federally endangered fishes, as estimated by regession显示文摘 | Beyera Daniel W Carlson Clarence A Keefe Thomas J | 1994 | Environmergal Toxicology and Chemistry1994，13，： | 1 |
| 8 | Maximum power point tracking for photovoltaic optimization using ripple-based extremum seeking control显示文摘 | Brunton Steven L Rowley Clarence W Kulkami Sanjecv R | 2010 | IEEE Transactions on Power Electronics2010，25，10： | 1 |
| 9 | Basic Research at Exxon 显示文摘 | Clarence M Eidt Jr Roger W Cohen | 1997 | Chemtech1997，，4： | 1 |
| 10 | Crohn's disease genotypes of patients in remission vs relapses after infliximab discontinuation显示文摘AIM:To investigate genetic differences between Crohn's disease(CD) patients with a sustained remission vs relapsers after discontinuing infliximab while in corticosteroid-free remission.METHODS:Forty-eight CD patients received infliximab and were in full corticosteroid-free clinical remission but then discontinued infliximab for reasons other than a loss of response,were identified by review of an electronic database and charts.Infliximab-associated remission was defined as corticosteroid-free plus normalization of clinical disease activity [CD activity index(CDAI) < 150] during follow-up visits based on physician global assessments.A CD relapse(loss of infliximab-induced remission) was clinically defined as a physician visit for symptoms of disease activity(CDAI > 220) and a therapeutic intervention with CD medication(s),or a hospitalization with complications related to active CD.Genetic analyses were performed on samples from 14 patients(n = 6 who had a sustained long term remission after stopping infliximab,n = 8 who rapidly relapsed after stopping infliximab).Nucleotide-binding oligomerization domain 2(NOD2)/caspase activation recruitment domain 15(CARD15) polymorphisms(R702W,G908R and L1007fs) and the inflammatory bowel disease 5(IBD5) polymorphisms(IGR2060a1 and IGR3081a1) were analyzed in each group.RESULTS:Five single nucleotide polymorphisms of IBD5 and NOD2/CARD15 genes were successfully analyzed for all 14 subjects.There was no significant increase in frequency of the NOD2/CARD15 polymorphisms(R702W,G908R and L1007fs) and the IBD5 polymorphisms(IGR2060a1 and IGR3081a1) in either group of patients;those whose disease relapsed rapidly or those who remained in sustained long term remission following the discontinuation of infliximab.Nearly a third of patients in full clinical remission who stopped infliximab for reasons other than loss of response remained in sustained clinical remission,while two-thirds relapsed rapidly.There was a marked difference in the duration of clinical remission following discontinuance of infliximab between the two groups.The patients who lost remission did so after 1.0 years ± 0.6 years,while those still in remission were at the time of this study,8.1 years ± 2.6 years post-discontinuation of infliximab,P < 0.001.The 8 patients who had lost remission after discontinuing infliximab had a mean number of 5 infusions(range 3-7),with a mean treatment time of 7.2 mo(range 1.5 mo-15 mo).The mean duration of time from the last infusion of infliximab to the time of loss of remission was 382 d(range 20 d-701 d).The 6 patients who remained in remission after discontinuing infliximab had a mean number of 6 infusions(range 3-12),with a mean treatment duration of 12 mo(range 3.6 mo-32 mo)(P = 0.45 relative to those who lost remission).CONCLUSION:There are no IBD5 or NOD2/CARD15 mutations that predict which patients might have sustained remission and which will relapse rapidly after stopping infliximab. | Cathy Lu Alistair Waugh Robert J Bailey Raeleen Cherry Levinus A Dieleman Leah Gramlich Kata Matic Mario Millan Karen I Kroeker Daniel Sadowski Christopher W Teshima Dennis Todoruk Clarence Wong Karen Wong Richard N Fedorak | 2012 | World Journal of Gastroenterology2012，18，36： | 1 |
| 11 | Reconstruction equations and the Karhunen-Loeve expansion for systems with symmetry显示文摘 | Jerrold M E | 2000 | Physica D2000，142，： | 1 |
| 12 | A machine-leaxning ap- proach to multi-robot coordination 显示文摘 | Wang Ying Clarence W de Silva | 2008 | Engineering Appli- cations of Artificial Intelligence2008，21，1： | 1 |
| 13 | Detection ofPCR arnplicons from bacterial pathogens using microsphere agglutination显示文摘 | SHAW J W ALEX C CLARENCE I K | 2004 | Journal of Microbiological Methods2004，56，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员